CFH and malignant hypertension: Further, patients with aHUS and MHT who were not treated with eculizumab were found to have a much higher proportion of pathogenic genetic variants or anti-CFH antibodies (33 [65%]) than those with aHUS and MHT who were treated with eculizumab (7 [35%]), or those with aHUS without MHT regardless of treatment status (treated, 152 [35%], not-treated, 230 [39%]).